B-Cell Malignancies—Expert Guidance on BTK Inhibitors for Today’s Clinic

In this clinic-focused program, review the latest data on current and emerging strategies leveraging BTK inhibitors to manage MCL, CLL, and other B-cell malignancies with an on-demand Webcast capturing expert discussion from the 2019 meeting in Chicago. Then download the meeting slidesets to help guide your treatment decisions.
Andrew D. Zelenetz, MD, PhD
Program Director
John C. Byrd, MD
Ian W. Flinn, MD, PhD

Downloadable Slidesets

In this downloadable slideset, Andrew D. Zelenetz, MD, PhD, examines the potential of combining BTK inhibitors with other therapies in patients with B-cell malignancies.

Andrew D. Zelenetz, MD, PhD
Program Director
Released: June 5, 2019

In this downloadable slideset, Ian W. Flinn, MD, PhD, examines optimal treatment approaches with BTK inhibitors in patients with B-cell malignancies.

Ian W. Flinn, MD, PhD Released: June 5, 2019

In this downloadable slideset, John C. Byrd, MD, discusses strategies for managing treatment-related adverse effects with BTK inhibitors in patients with B-cell malignancies.

John C. Byrd, MD Released: June 5, 2019

In this downloadable slideset, John C. Byrd, MD, provides the rationale for targeting BTK with inhibitors in patients with B-cell malignancies.

John C. Byrd, MD Released: June 5, 2019

On-Demand Webcast

In this on-demand Webcast of a CCO symposium at ASCO 2019, expert faculty review and discuss the latest data on using BTK inhibitors in the treatment of patients with B-cell malignancies.

Andrew D. Zelenetz, MD, PhD
Program Director
John C. Byrd, MD Ian W. Flinn, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 11, 2019 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue